U.S. markets open in 4 hours 22 minutes
  • S&P Futures

    +52.00 (+1.13%)
  • Dow Futures

    +300.00 (+0.85%)
  • Nasdaq Futures

    +262.50 (+1.66%)
  • Russell 2000 Futures

    +30.90 (+1.40%)
  • Crude Oil

    +1.81 (+2.60%)
  • Gold

    +2.40 (+0.13%)
  • Silver

    +0.15 (+0.68%)

    -0.0014 (-0.12%)
  • 10-Yr Bond

    0.0000 (0.00%)
  • Vix

    -6.83 (-22.27%)

    +0.0001 (+0.00%)

    +0.1840 (+0.16%)

    +3,623.54 (+7.61%)
  • CMC Crypto 200

    +64.07 (+5.08%)
  • FTSE 100

    +79.07 (+1.09%)
  • Nikkei 225

    +528.23 (+1.89%)

Viveve to Host Conference Call to Provide Corporate Update and Second Quarter 2019 Results on August 8, 2019

  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

ENGLEWOOD, CO / ACCESSWIRE / August 1, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women’s intimate health, today announced that it will report its second quarter 2019 financial results after the close of the U.S. financial markets on Thursday, August 8, 2019, and will host a live conference call and webcast to provide a corporate update at 4:30 PM ET the same day.

The conference call may be accessed by dialing 1-833-255-2833 (domestic) or 1-412-902-6728 (international) or via live webcast at https://services.choruscall.com/links/vive190808.html. Participants may also pre-register for the conference call at http://dpregister.com/10133641.

A recording of the webcast will be posted on the company’s investor relations website following the call at ir.viveve.com and will be available online for 90 days.

About Viveve

Viveve Medical, Inc. is a medical technology company focused on women's intimate health. Viveve is committed to advancing new solutions to improve women's overall well-being and quality of life. The internationally patented Viveve® System incorporates cryogen-cooled monopolar radiofrequency (CMRF) technology to uniformly deliver volumetric heating while gently cooling surface tissue to generate neocollagenesis in a single in-office session.

International regulatory approvals and clearances have been received for vaginal laxity and/or improvement in sexual function indications in over 50 countries. Viveve is conducting VIVEVE II, a multicenter, randomized, double-blind, sham-controlled clinical trial to assess improvement of sexual function in women following vaginal childbirth. Completion of full 250 subject enrollment was announced in early March 2019. If successful, VIVEVE II results could support a marketing application for a new U.S. commercial indication. Currently, in the United States, the Viveve® System is cleared by the FDA for use in general surgical procedures for electrocoagulation and hemostasis.

For more information visit Viveve's website at www.viveve.com.

Safe Harbor Statement

All statements in this press release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. While management has based any forward-looking statements included in this press release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of our control, which could cause actual results to materially differ from such statements. Such risks, uncertainties and other factors include, but are not limited to, the fluctuation of global economic conditions, the performance of management and our employees, our ability to obtain financing or pursue strategic alternatives, our ability to obtain approval or clearance for sale of our medical device for all indications sought, competition, general economic conditions and other factors that are detailed in our periodic and current reports available for review at www.sec.gov. Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware, unless required by law.

Viveve is a registered trademark of Viveve, Inc.

Investor Relations contacts:

Sarah McCabe
Stern Investor Relations, Inc.
(212) 362-1200


Amato and Partners, LLC
Investor Relations Counsel


Media contact:

Jenna Iacurci
Berry & Company Public Relations
(212) 253-8881


SOURCE: Viveve Medical, Inc.

View source version on accesswire.com: